Equities research analysts expect OncoSec Medical Inc (NASDAQ:ONCS) to report earnings per share of ($0.23) for the current quarter, Zacks reports. Zero analysts have made estimates for OncoSec Medical’s earnings. OncoSec Medical posted earnings of ($0.29) per share during the same quarter last year, which indicates a positive year over year growth rate of 20.7%. The business is expected to report its next quarterly earnings report on Thursday, January 18th.
According to Zacks, analysts expect that OncoSec Medical will report full-year earnings of ($0.86) per share for the current year. For the next financial year, analysts forecast that the firm will report earnings of ($0.71) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover OncoSec Medical.
OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.05).
OncoSec Medical (NASDAQ ONCS) traded down $0.06 on Friday, hitting $1.94. The stock had a trading volume of 358,977 shares, compared to its average volume of 738,917. The stock has a market capitalization of $68.90, a P/E ratio of -1.88 and a beta of 3.27. OncoSec Medical has a 1 year low of $0.88 and a 1 year high of $2.95.
COPYRIGHT VIOLATION WARNING: This report was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://theolympiareport.com/2018/01/14/426212.html.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.